Pterostilbene is resveratrol’s better-dressed cousin. Structurally they are almost the same molecule — a stilbene backbone — but pterostilbene swaps two of resveratrol’s three hydroxyl groups for methyl (methoxy) groups. That small chemical edit changes the one thing that most undermined resveratrol as a supplement: how much of it actually survives the trip into your blood. It is a genuine improvement, and it is also almost the entire story — the human evidence that the better absorption matters for anything you’d take it for is still slim.
The one thing it genuinely does better: absorption
Resveratrol’s central problem is that it’s absorbed but then conjugated (glucuronidated and sulfated) so fast that almost none of the intact molecule reaches circulation. Replacing two hydroxyls with methyl groups removes two of those handles for conjugation and makes the molecule more fat-soluble, so more of it gets through intact and it lingers longer. A head-to-head rodent pharmacokinetic study found pterostilbene’s oral bioavailability was roughly 80%, versus about 20% for resveratrol, with a correspondingly higher and longer-lasting blood exposure.[1] If you were designing a stilbene to actually reach tissues, this is what you’d build. That is the legitimate case for pterostilbene.
The mechanism story: same family, same caveats
Mechanistically pterostilbene is pitched like resveratrol: an antioxidant and sirtuin-adjacent compound that, in cell and animal models, modulates oxidative stress, inflammation, and metabolic and neurologic pathways. A review of the preclinical literature catalogs antioxidant activity and disease-modifying effects across a range of animal models — metabolic, cardiovascular, oncologic and neurologic.[2] As with resveratrol, this is real, interesting biology, and it is almost entirely preclinical. “Activates sirtuins in a dish” and “modifies disease in a rodent” are hypotheses about humans, not findings in them.
What actually happened in people
Human data on pterostilbene come down to a small, related pair of trials from one group. A safety analysis found pterostilbene was well tolerated at the doses studied, with no signal of harm to liver, kidney or glucose markers — useful, but a safety readout, not proof of benefit.[3] The efficacy trial randomized 80 adults with elevated cholesterol to pterostilbene (125 mg or 50 mg twice daily), a pterostilbene-plus-grape-extract combination, or placebo for 6–8 weeks. High-dose pterostilbene lowered blood pressure meaningfully (about 7.8/7.3 mmHg) and produced minor weight loss in people not already on cholesterol medication.[4] That’s the good news — and it’s a surrogate-marker result in one small, short study.
| Setting | What pterostilbene did |
|---|---|
| Rat pharmacokinetics | ~80% oral bioavailability vs ~20% for resveratrol |
| Cell / animal models | Antioxidant, anti-inflammatory, metabolic effects (preclinical) |
| Humans — safety | Well tolerated, no organ or glucose harm signal |
| Humans — blood pressure | High dose lowered BP ~7.8/7.3 mmHg (one small trial) |
| Humans — LDL cholesterol | Monotherapy raised LDL ~17 mg/dL (caution) |
| Humans — longevity / aging | No trials; claims extrapolated from mechanism |
Where the marketing gets ahead of the evidence
Pterostilbene is frequently sold as a longevity or “NAD+” ingredient, often co-formulated with NMN in anti-aging stacks. It’s worth being precise: pterostilbene is not an NAD+ precursor, and no human trial has tested it against aging, lifespan, or the biological-age endpoints the packaging gestures at. Its longevity rationale is the same sirtuin-and-antioxidant mechanism story as resveratrol’s — and resveratrol is the field’s cautionary tale precisely because that story didn’t survive contact with human trials. Better absorption fixes resveratrol’s most obvious weakness; it does not, by itself, generate the missing outcome data.
Safety
At the doses studied, pterostilbene was well tolerated with no adverse signal on liver, kidney or glucose parameters.[3] The most concrete flag from human data is the LDL increase seen with monotherapy in the metabolic trial.[4] As a methoxylated stilbene it’s plausible it shares resveratrol’s tendency to interact with drug-metabolizing enzymes, but that hasn’t been characterized in people — another reason for caution if you take prescription medication.
The honest bottom line
Pterostilbene is the rare case where the “improved version” claim is chemically true: two methyl groups really do give it far better oral bioavailability than resveratrol.[1] But pharmacokinetics is a means, not an outcome. The human evidence is two small, short trials of metabolic markers from one group — a blood-pressure benefit shadowed by an LDL increase — and nothing at all on aging.[3][4] If you’re drawn to it as a longevity supplement, hold it to the same standard the field learned to apply to resveratrol: impressive mechanism, better delivery, unproven benefit.